clinical trial · NCT07484204
Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
Anxo Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 48
SchizophreniaAX251 LAI 45 mgAX251 LAI 90 mgAX251 LAI 135 mgAX251 LAI 180 mg
brief summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.
started
Jul 1, 2026
primary completion
Jul 1, 2028
completion
Jul 1, 2028
last updated
Mar 20, 2026
official title
An Open-label, Multicenter Study to Determine the Pharmacokinetics, Safety, and Tolerability of AX251 Long-Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol